Enlivex Therapeutics Gets Green Light for Phase I Trial
Ticker: ENLV · Form: 6-K · Filed: Jul 23, 2024 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial, regulatory-approval, drug-development
TL;DR
Enlivex cleared for Phase I trial by Israeli Ministry of Health.
AI Summary
On July 23, 2024, Enlivex Therapeutics Ltd. announced that the Israeli Ministry of Health has authorized the initiation of a Phase I clinical trial for their drug candidate. This trial will evaluate the drug's safety and tolerability in healthy volunteers.
Why It Matters
Regulatory approval for a Phase I trial is a crucial step in drug development, indicating the potential for a new therapeutic option if successful.
Risk Assessment
Risk Level: medium — Clinical trial initiations are inherently risky due to the high failure rate in drug development, but this is an early-stage approval.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Israeli Ministry of Health (company) — Regulatory body authorizing the trial
- July 23, 2024 (date) — Date of announcement
FAQ
What is the primary purpose of the authorized Phase I clinical trial?
The Phase I clinical trial is authorized to evaluate the safety and tolerability of the drug candidate in healthy volunteers.
Which regulatory body authorized the Phase I trial?
The Israeli Ministry of Health authorized the initiation of the Phase I clinical trial.
When was the announcement regarding the trial authorization made?
The announcement was made on July 23, 2024.
What is the name of the company making this announcement?
The company making the announcement is Enlivex Therapeutics Ltd.
What is the previous name of Enlivex Therapeutics Ltd.?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-07-23 08:02:02
Filing Documents
- ea0209432-6k_enlivex.htm (6-K) — 9KB
- ea020943201ex99-1_enlivex.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001213900-24-063313.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer Date: July 23, 2024 2